Virology drug development now includes therapies targeting viral replication, entry, proteases, polymerases, host pathways and immune responses. Companies are also developing long-acting and combination treatments for HIV, hepatitis, influenza, COVID-19 and emerging infections. Major players include Gilead Sciences, Pfizer, Merck, Johnson & Johnson, GSK, AbbVie and Roche.
Understand Company Moves, Investments, Sales And What Customers Are Looking For. Download Sample: https://www.towardshealthcare.com/download-sample/5713
Leading Companies in Innovative Virology Drugs
| Company | Key virology focus | Representative medicines | Key strength |
|---|---|---|---|
| Gilead Sciences | HIV, hepatitis B/C, COVID-19 | Biktarvy, Descovy, Vemlidy, Veklury | Large antiviral portfolio |
| Merck & Co. | HIV, COVID-19, emerging viruses | Isentress, Lagevrio | Antiviral and infectious disease R&D |
| Pfizer | COVID-19, infectious diseases | Paxlovid, Abrysvo | Antiviral and vaccine capabilities |
| GSK | HIV, herpes, respiratory viruses | Dovato, Juluca, Rukobia | Long-term HIV innovation |
| Johnson & Johnson | HIV and infectious disease | Symtuza, Prezcobix | HIV combination therapy |
| Roche | Influenza, hepatitis, emerging infections | Xofluza, Tamiflu partnerships | Antiviral innovation and diagnostics |
| AbbVie | HIV, hepatitis C | Mavyret, Rinvoq-related infectious disease research | HCV and immunology expertise |
| Shionogi | Influenza, COVID-19 | Xofluza, Xocova | Oral antiviral development |
| Atea Pharmaceuticals | Hepatitis C, COVID-19 | Sofosbuvir-related programs | Nucleotide antiviral research |
| Aligos Therapeutics | Hepatitis B | HBV pipeline candidates | Chronic HBV innovation |
Gilead Sciences
Gilead Sciences is one of the most important global companies in antiviral medicine, particularly in HIV and viral hepatitis.
Its HIV portfolio includes Biktarvy, Descovy, Genvoya, Odefsey and Sunlenca, while its hepatitis portfolio includes medicines such as Vemlidy and Vosevi.
Gilead reported $28.4 billion in product sales in 2025, with its HIV franchise remaining one of its largest business areas.
HIV innovation
Gilead’s HIV strategy is increasingly focused on reducing dosing frequency.
In 2025, the FDA approved Yeztugo, a twice-yearly injectable formulation of lenacapavir for HIV pre-exposure prophylaxis.
Gilead reported that the PURPOSE 1 and PURPOSE 2 studies demonstrated 100% efficacy in preventing HIV infection among participants receiving twice-yearly lenacapavir in the relevant study populations.
This represents a major shift from daily oral prevention toward twice-yearly administration.
Merck & Co.
Merck has significant expertise in infectious diseases and antiviral development.
Its HIV portfolio includes Isentress, while its COVID-19 antiviral Lagevrio (molnupiravir) was developed with Ridgeback Biotherapeutics.
Merck reported $65.0 billion in worldwide sales in 2025, demonstrating the scale of its broader pharmaceutical business.
Emerging infectious disease focus
Merck continues to invest in infectious-disease research across antiviral mechanisms and vaccines.
For healthcare providers, its importance extends beyond one antiviral product because the company has capabilities spanning:
- Antiviral medicines
- Vaccines
- Infectious disease research
- Clinical development
- Diagnostic partnerships
Pfizer
Pfizer became one of the most visible antiviral companies during the COVID-19 pandemic through Paxlovid, an oral antiviral combining nirmatrelvir and ritonavir.
Paxlovid targets SARS-CoV-2 protease activity and is used for patients at increased risk of progression to severe COVID-19.
Pfizer reported $62.6 billion in total company revenue in 2025.
Pfizer’s broader infectious disease strategy
Pfizer also operates in:
- Vaccines
- Antiviral therapies
- Respiratory infections
- Infectious disease prevention
- Emerging pathogen research
Its combination of vaccine and antiviral capabilities gives healthcare systems access to both prevention and treatment solutions.
GSK
GSK has a major presence in HIV treatment through its ViiV Healthcare business, a joint venture involving GSK, Pfizer and Shionogi.
Its HIV portfolio includes Dovato, Juluca, Triumeq and Rukobia.
GSK reported £32.0 billion in 2025 sales, with specialty medicines and HIV remaining important parts of its pharmaceutical portfolio.
Long acting HIV treatment
GSK and ViiV have invested heavily in reducing dosing frequency.
Cabenuva, a long-acting injectable combination of cabotegravir and rilpivirine, can be administered every two months for eligible patients.
ViiV also markets Apretude, a long-acting injectable HIV prevention medicine administered every two months after the initial dosing schedule.
This approach addresses a major challenge in HIV treatment and prevention, which is maintaining adherence to daily medication.
Johnson & Johnson
Johnson & Johnson has a long history in HIV treatment through its Janssen pharmaceutical business.
Its portfolio includes:
- Symtuza
- Prezcobix
- Edurant
- Intelence
The company has contributed to combination HIV treatment strategies that allow healthcare providers to manage patients using increasingly simplified regimens.
J&J also continues to invest in infectious disease research through its pharmaceutical and vaccine capabilities.
Roche
Roche is particularly important in influenza and antiviral diagnostics.
Its influenza antiviral Xofluza (baloxavir marboxil) uses a different mechanism from neuraminidase inhibitors and is designed as a single-dose oral treatment.
Roche also combines pharmaceutical development with diagnostics, giving healthcare providers tools across:
Detection + diagnosis + treatment + monitoring
This integrated model is particularly important for viral infections where rapid identification can influence treatment decisions.
Shionogi
Shionogi has established itself as a specialist antiviral company.
Its influenza treatment Xofluza was developed using a novel mechanism that inhibits the influenza cap-dependent endonuclease.
The company also developed Xocova (ensitrelvir) for COVID-19 treatment in Japan.
Shionogi’s strategy illustrates the role of specialized pharmaceutical companies in developing mechanism-specific antiviral drugs rather than relying only on broad-spectrum approaches.
AbbVie
AbbVie has a major historical presence in viral hepatitis.
Its hepatitis C combination Mavyret became an important treatment option because of its high cure rates and relatively short treatment duration.
Modern direct-acting antiviral therapy has transformed hepatitis C treatment, with current regimens capable of achieving cure rates above 95% in many patient populations.
AbbVie’s broader infectious disease expertise now overlaps with immunology, where managing viral risks and immune-mediated disease can be clinically important.
Aligos Therapeutics
Aligos is a biotechnology company focused heavily on chronic hepatitis B and other viral diseases.
Its HBV research focuses on developing therapies that could potentially move treatment beyond long-term viral suppression toward functional cure approaches.
This is important because hepatitis B remains a major global health problem despite the availability of effective antiviral suppression.
The WHO estimates that approximately 254 million people were living with chronic hepatitis B in 2022, with around 1.1 million deaths annually attributed to hepatitis B and its complications.
Atea Pharmaceuticals
Atea focuses on antiviral drug development, particularly nucleotide-based approaches.
Its pipeline has included programs targeting hepatitis C and SARS-CoV-2.
The company is an example of a smaller biotechnology player attempting to compete with large pharmaceutical companies through specialized antiviral platforms.
Major Virology Treatment Areas
| Viral disease | Major companies | Innovation direction |
|---|---|---|
| HIV | Gilead, GSK/ViiV, J&J, Merck | Long-acting treatment and prevention |
| Hepatitis B | Gilead, Aligos, Assembly-related programs | Functional cure research |
| Hepatitis C | Gilead, AbbVie | Short-duration curative treatment |
| Influenza | Roche, Shionogi | Single-dose and mechanism-specific antivirals |
| COVID-19 | Pfizer, Merck, Shionogi | Oral antiviral treatment |
| Emerging viruses | Multiple biotech and pharma companies | Broad-spectrum antivirals |
| Respiratory viruses | Pfizer, Roche, GSK and others | Antivirals and prevention |
What Is Driving Innovation in Virology?
Several major trends are changing antiviral drug development.
Long Acting Antivirals
The move from daily pills toward monthly, bimonthly or twice-yearly administration is one of the biggest developments.
Gilead’s twice-yearly HIV prevention approach is an important example.
Oral Antivirals
Oral treatment can reduce the need for hospital-based administration.
Paxlovid and Xofluza demonstrate how oral antivirals can provide relatively convenient treatment options for selected viral infections.
Combination Therapy
Combining antiviral mechanisms can:
- Reduce resistance
- Improve treatment effectiveness
- Simplify regimens
- Expand treatment options
Functional Cure Research
Hepatitis B remains a major target because existing medicines generally suppress the virus rather than eliminate it.
The development goal is increasingly focused on functional cure, where sustained viral control may be achieved without lifelong treatment.
Antiviral Resistance
Resistance remains one of the most important challenges.
Companies are therefore developing medicines with:
- New mechanisms
- Higher genetic barriers to resistance
- Combination regimens
- More durable antiviral activity
Who Are the Actual Buyers?
Healthcare providers are not the only buyers of innovative virology drugs.
Hospitals
Hospitals purchase antivirals for:
- Inpatient treatment
- High-risk patients
- Emergency treatment
- Infectious disease departments
Health Systems
Large integrated health systems evaluate:
- Clinical effectiveness
- Total treatment cost
- Formulary positioning
- Patient outcomes
- Administration requirements
Specialty Clinics
Infectious disease, HIV and hepatology clinics are important buyers for:
- HIV medicines
- Hepatitis treatments
- Long-acting antivirals
- Complex antiviral regimens
Government Healthcare Programs
Government purchasers and public health programs can represent substantial demand for antivirals, particularly for HIV, hepatitis and pandemic preparedness.
Retail and Specialty Pharmacies
Pharmacies distribute many oral antiviral treatments and chronic virology medicines.
Specialty pharmacies are particularly important for expensive or complex therapies requiring patient monitoring and support.
Payers and PBMs
Insurance companies and pharmacy benefit managers influence access through:
- Formularies
- Reimbursement
- Prior authorization
- Step therapy
- Copay structures
For pharmaceutical companies, payer access can be as important as clinical differentiation.
Competitive Landscape
The virology market is highly competitive.
Key competitors include:
- Gilead Sciences
- GSK/ViiV Healthcare
- Merck & Co.
- Pfizer
- Johnson & Johnson
- Roche
- AbbVie
- Shionogi
- Aligos Therapeutics
- Atea Pharmaceuticals
Competition increasingly centers on:
- Efficacy
- Resistance profile
- Dosing frequency
- Treatment duration
- Safety
- Patient adherence
- Manufacturing scale
- Price and reimbursement
- Convenience of administration
What Healthcare Providers Should Track
Healthcare providers evaluating innovative antiviral medicines should monitor:
Clinical evidence: How strong is the evidence across relevant patient populations?
Dosing: Can treatment move from daily administration toward long-acting dosing?
Resistance: What is the medicine’s resistance profile?
Safety: What adverse events and drug interactions should clinicians consider?
Access: Is the medicine covered by major payers?
Cost: What is the total cost of treatment rather than simply the list price?
Patient adherence: Does the formulation make long-term treatment easier?
Supply: Can manufacturers maintain reliable supply during demand increases?
The Strategic Takeaway
The next phase of virology innovation is increasingly about durability, convenience and precision, rather than simply developing another antiviral molecule.
Gilead is pushing HIV prevention toward twice-yearly administration.
GSK/ViiV has established long-acting HIV treatment and prevention.
Pfizer and Merck have demonstrated the importance of convenient oral COVID-19 antivirals.
Roche and Shionogi have introduced mechanism-specific approaches to influenza treatment.
Meanwhile, biotechnology companies such as Aligos are targeting the much harder challenge of functional cure for chronic hepatitis B.
For healthcare providers, the important question is therefore not simply which company has the newest antiviral.
It is:
Which treatment provides the strongest combination of clinical benefit, durability, convenience, safety, access and affordability for the patient population being treated?
How Towards Healthcare Research & Consulting Can Help
Towards Healthcare Research & Consulting can help pharmaceutical companies, healthcare providers, investors and other stakeholders track:
- Virology drug pipelines
- Antiviral clinical trials
- Drug launches
- Company sales and revenue
- Competitive portfolios
- Patent and regulatory activity
- Long-acting antiviral development
- HIV and hepatitis markets
- Emerging viral disease opportunities
- Hospital and specialty-provider demand
- Payer and reimbursement trends
- Regional market opportunities
The objective is to connect clinical innovation, pharmaceutical competition, patient needs, healthcare-provider demand and market opportunities to support better strategic decisions.
Connect with us for complete guidance or further enquiry at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium